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Mutation position and type of substitution in the /?-subunit of the RNA
polymerase influence in-vitro activity of rifamycins in rifampicin-resistant
Mycobacterium tuberculosis
Thomas Bodmer, Gabriela Zurcher, Paul Imboden and Amalio Telenti
Institute for Medical Microbiology, University of Berne, CH-3010 Bern, Switzerland
Quantitative susceptibility testing for rifampicin, rifabutin and rifapentine of 36
Mycobacterium tuberculosis isolates with known sequences for the gene encoding for
the RNA polymerase /?-subunit (rpoB) revealed that both mutation position and type
of amino acid substitution influence the in-vitro activity of rifamycins in
rifampicin-resistant strains.
Introduction
In Mycobacterium tuberculosis, the substitution of a limited number of highly conserved
amino acids encoded by the rpoB gene, which codes for the /?-subunit of the RNA
polymerase, was shown to be associated with rifampicin (RMP) resistance (Telenti et al.,
1993a), and was confirmed by studies of genetic complementation (Miller, Crawford &
Shinnick, 1994). To date, no additional mechanisms of resistance, such as a permeability
barrier (Hui, Gordon & Kajioka, 1977), have been shown to contribute significantly to
RMP resistance in M. tuberculosis. Some RMP-resistant strains of M. tuberculosis remain
susceptible to the spiro-piperidyl rifamycin rifabutin (RBU) (Delia Bruna et al., 1983;
Dickinson & Mitchison, 1987), and some patients with RMP-resistant pulmonary
tuberculosis have shown a favourable clinical and bacteriological response to this drug
(Gillespie et al., 1990; Hong Kong Chest Service/Tuberculosis Research Centre, 1992;
Pretet et al., 1992). We determined the MICs of RMP, RBU, and rifapentine (RPE)
(Dickinson & Mitchison, 1987) for RMP-resistant strains of M. tuberculosis with known
rpoB sequences to assess whether there was a correlation between the level of resistance
to various rifamycins and specific mutations in the rpoB gene.
Material and methods
Strains
The following strains of M. tuberculosis were examined: H37 rv (Institut Pasteur
14001.0001), and 10 RMP-susceptible and 26 RMP-resistant clinical isolates. The latter
strains have been characterised by partial sequencing of rpoB, and represented 14
RMP-resistance mutations (Telenti et al., 1993a). All of the RMP-resistant strains
exhibited resistance to one or more additional first-line antituberculosis drugs. When
available three different isolates per mutation were examined.
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Antibiotics
RMP was provided by Ciba-Geigy Ag, Basle, Switzerland, RPE by Marion Merrell Dow
Inc., Cincinatti, U.S.A., and RBU by Farmitalia Carlo Erba, Milan, Italy. RMP and RPE
were dissolved in dimethyl-sulfoxide, and RBU in dimethyl-formamide. Stock solutions
of each antibiotic (320 mg/L) were freshly prepared for each run in 0067 M phosphate
buffer, pH 70. Working solutions ranging from 0015 mg/L to 80 mg/L were made by
serial two-fold dilutions with distilled water.
MICs
The MICs of the test antibiotics were determined by a radiometric method (Heifets, 1991).
Briefly, BACTEC 12B vials containing 4 mL 7H12 medium were inoculated with 0-1 mL
of a subculture of the test organisms adjusted to McFarland 0-5 in distilled water, and
then incubated at 37°C until the growth index (GI) reached 500-800. A 0-1 mL aliquot
of this suspension was then inoculated into the BACTEC 12B vial with or without
appropriate dilutions of the test antibiotic. To prepare a 1% control vial, 01 mL of the
100-fold dilution of the inoculum described above was inoculated into an antibiotic free
12B vial. The 12B vials were incubated at 37CC and GI readings were recorded daily, using
the BACTEC 460 TB instrument (Johnston Laboratories, Inc., Sparks, MD, USA), until
the 1 % control vial reached a GI of > 30. When the daily increases in the GI of the
antibiotic-containing vial and its final GI reading were lower than those for the 1%
control, the antibiotic was considered to have inhibited more than 99% of the bacterial
population, and this concentration was defined as the MIC.
Results and discussion
Most of the mutations studied, that is those located at amino acid positions 513, 526 and
531 of RpoB, were associated with high level cross-resistance to RBU and RPE
( M I O 4 - 0 mg/L). However, in the present study, five of 14 mutant alleles, at positions
511,516,518 and 522, were associated with MIC values between 0-25 and 1 0 mg/L RBU
(Table). By comparing radiometrically determined MICs with the concentrations of RBU
achievable in blood, M. tuberculosis strains were tentatively separated into the categories
susceptible (MIC < 012 mg/L), moderately susceptible (MIC 0-25 mg/L), resistant
(MIC 0-5 mg/L), and very resistant (MIC> 0-5 mg/L) (Heifets, 1991). According to these
criteria it appears that strains with mutations at amino acid position 511, 516, and 522
in the RpoB remain moderately susceptible to RBU, or exhibit low level resistance only.
However, relying on serum concentrations when defining breakpoints for RBU is
probably a conservative approach, since the achievable concentrations of this antibiotic
are higher in tissue than in plasma (Delia Bruna et al., 1983). At present, clinical
experience in the treatment of RMP-resistant tuberculosis with RBU is limited, but there
is evidence of its beneficial effect in some patients with multidrug-resistant tuberculosis
(Gillespie et al., 1990; Pretet et al., 1992). In one study, the initial responses in the two
patients infected with RBU-susceptible M. tuberculosis were among the best, although
rapid development of RBU resistance was seen (Hong Kong Chest Service/Tuberculosis
Research Centre, 1992). Experimental studies in animals and controlled clinical trials
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Table. Comparison ofrpoB genotype and antimicrobial susceptibility test results for 36 isolates of
M. tuberculosis.
Genotype
mutation amino acid isolates
position1 substitution (n) rifampicin
Phenotype
MIC (mg/L)
rifabutin rifapentin
Wild type
Leu 511
Gin 513
Asp 516
Asp 516
Asn 518
Ser522
His 526
His 526
His 526
His 526
His 526;
Val 498
Ser531
Ser531
Ser531
wild type
Pro
Leu
Tyr
Val
deletion
Leu
Arg
Asp
Pro
Tyr
Gin; Ala
Leu
Trp
Tyr
10
1
1
2
3
1
1
2
3
2
3
2
3
1
1
0-25-0-5
>80
>80
20
3f 8-0
>80
>80
>80
>80
>80
>80
>80
>80
>80
>80
<0015-O125
0-5
>80
0-25
0-25-0-5
10
0-5
>80
>80
>80
>80
80
4-0->80
80
>80
<0015-0125
>80
>80
0-5
4O->80
40
80
>80
>80
>80
>80
>80
>80
>80
>80
•Numbers correspond to E. colt RNA polymerase amino acid positions.
which address the efficacy of RBU in the treatment of infections caused by this subset
of RMP-resistant strains are needed.
The second main observation of this study relates to the conventional understanding
of the emergence of resistance to RMP. According to the current view, the development
of resistance to RMP in M. tuberculosis is a single-step event leading to high-level
resistance. Mutants arise spontaneously in strains not previously exposed to the antibiotic
at a frequency of 10~M0~8 cells. Our results suggest, however, that not only with RBU
but also with RMP, the level of resistance is dependent on the type of mutation involved.
For example, substitution of aspartate for tyrosine at position 516 in two unlinked isolates
only resulted in moderately susceptible strains with MICs of 20 mg/L. In contrast, three
isolates with substitution of valine for aspartate at the same position exhibited high-level
resistance with MICs above 8 mg/L.
The observed MIC values of RPE for the various mutant strains were similar to those
observed with RMP.
Investigation of the RpoB substitutions associated with rifamycin resistance combined
with the careful delineation of the phenotype by quantitative susceptibility testing may
help in identifying new compounds that retain their efficacy in the presence of specific
mutations, thus revealing new insights of the interactions between rifamycins and
mycobacterial RNA polymerase. In addition, since the activity of RBU in RMP-resistant
M. tuberculosis seemingly depends on both the mutation position and the type of
substitution in rpoB, direct sequencing (Telenti et al., 1993a) or polymerase chain
reaction-single-strand conformation polymorphism analysis, which is a recently applied
molecular tool for the direct detection of mutations in rpoB (Telenti et al., 19936), could
predict moderate susceptibility or low level resistance to RBU within 24 h. The
availability of this information at a very early stage of treatment might substantially
influence the management of patients with multidrug-resistant tuberculosis.
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